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A B S T R A C T
Background
Acute bronchiolitis is a significant burden on children, their families and healthcare facilities. It mostly aDects children younger than
two years of age. Treatment involves adequate hydration, humidified oxygen supplementation, and nebulisation of medications, such as
salbutamol, epinephrine, and hypertonic saline. The eDectiveness of magnesium sulphate for acute bronchiolitis is unclear.
Objectives
To assess the eDects of magnesium sulphate in acute bronchiolitis in children up to two years of age.
Search methods
We searched CENTRAL, MEDLINE, Embase, LILACS, CINAHL, and two trials registries to 30 April 2020. We contacted trial authors to identify
additional studies. We searched conference proceedings and reference lists of retrieved articles. Unpublished and published studies were
eligible for inclusion.
Selection criteria
Randomised controlled trials (RCTs) and quasi-RCTs, comparing magnesium sulphate, alone or with another treatment, with placebo or
another treatment, in children up to two years old with acute bronchiolitis. Primary outcomes were time to recovery, mortality, and adverse
events. Secondary outcomes were duration of hospital stay, clinical severity score at 0 to 24 hours and 25 to 48 hours a@er treatment,
pulmonary function test, hospital readmission within 30 days, duration of mechanical ventilation, and duration of intensive care unit stay.
Data collection and analysis
We used standard methodological procedures expected by Cochrane. We used GRADE methods to assess the certainty of the evidence.
Main results
We included four RCTs (564 children). One study received funding from a hospital and one from a university; two studies did not report
funding sources. Comparator interventions diDered among all four trials. Studies were conducted in Qatar, Turkey, Iran, and India. We
assessed two studies to be at an overall low risk of bias, and two to be at unclear risk of bias, overall. The certainty of the evidence for all
outcomes and comparisons was very low except for one: hospital re-admission rate within 30 days of discharge for magnesium sulphate
versus placebo. None of the studies measured time to recovery, duration of mechanical ventilation, duration of intensive care unit stay,
or pulmonary function.
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There were no events of mortality or adverse eDects for magnesium sulphate compared with placebo (1 RCT, 160 children). The eDects of
magnesium sulphate on clinical severity are uncertain (at 0 to 24 hours: mean diDerence (MD) on the Wang score 0.13, 95% confidence
interval (CI) -0.28 to 0.54; and at 25 to 48 hours: MD on the Wang score -0.42, 95% CI -0.84 to -0.00). Magnesium sulphate may increase
hospital re-admission rate within 30 days of discharge (risk ratio (RR) 3.16, 95% CI 1.20 to 8.27; 158 children; low-certainty evidence).
None of our primary outcomes were measured for magnesium sulphate compared with hypertonic saline (1 RCT, 220 children). EDects
were uncertain on the duration of hospital stay in days (MD 0.00, 95% CI -0.28 to 0.28), and on clinical severity on the Respiratory Distress
Assessment Instrument (RDAI) score at 25 to 48 hours (MD 0.10, 95% CI -0.39 to 0.59).
There were no events of mortality or adverse eDects for magnesium sulphate, with or without salbutamol, compared with salbutamol (1
RCT, 57 children). EDects on the duration of hospital stay were uncertain (magnesium sulphate: 24 hours (95% CI 25.8 to 47.4), magnesium
sulphate + salbutamol: 20 hours (95% CI 15.3 to 39.0), and salbutamol: 24 hours (95% CI 23.4 to 76.9)).
None of our primary outcomes were measured for magnesium sulphate + epinephrine compared with no treatment or normal saline +
epinephrine (1 RCT,120 children). EDects were uncertain for the duration of hospital stay in hours (MD -0.40, 95% CI -3.94 to 3.14), and for
RDAI scores (0 to 24 hours: MD -0.20, 95% CI -1.06 to 0.66; and 25 to 48 hours: MD -0.90, 95% CI -1.75 to -0.05).
Authors' conclusions
There is insuDicient evidence to establish the eDicacy and safety of magnesium sulphate for treating children up to two years of age with
acute bronchiolitis. No evidence was available for time to recovery, duration of mechanical ventilation and intensive care unit stay, or
pulmonary function. There was no information about adverse events for some comparisons. Well-designed RCTs to assess the eDects of
magnesium sulphate for children with acute bronchiolitis are needed. Important outcomes, such as time to recovery and adverse events
should be measured.
P L A I N   L A N G U A G E   S U M M A R Y
Magnesium sulphate for treating children up to two years old with bronchiolitis
Review question
We investigated the eDectiveness and safety of magnesium sulphate for treating children up to two years old with acute bronchiolitis.
Background
Acute bronchiolitis is caused by a virus, and mostly aDects children up to two years old. This condition blocks small airways in the lungs,
causing coughing, wheezing, and breathing diDiculties. Usual treatment involves supportive care, which includes providing adequate fluids
and humidified oxygen. Children with bronchiolitis may need intensive care treatment.
Search date
Evidence is current to 30 April 2020.
Study characteristics
We included four studies (564 children) conducted in Qatar, Turkey, Iran, and India. Three studies included children with moderate to severe
bronchiolitis. Studies compared magnesium sulphate, given via a tube into a vein (intravenous), or as a fine inhaled spray (nebulised),
with a dummy treatment (known as a placebo – something that looks like magnesium sulphate treatment), medicines to open the airways
(salbutamol or epinephrine), a salt water solution (hypertonic saline), or no treatment.
Study funding sources
One study received funding from a hospital and one from a university; two studies did not report funding sources.
Key results
There was not enough evidence to know if intravenous or nebulised magnesium sulphate, either alone or combined with other treatments,
improved bronchiolitis outcomes in children up to two years old. We could not determine if magnesium sulphate reduced deaths,
unexpected medical problems during treatment, time spent in hospital, or illness severity (based on doctors' clinical assessment scores).
Time taken to recovery was not measured.
Certainty of the evidence
Overall, we are very uncertain of the results.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Magnesium sulphate compared with placebo for acute bronchiolitis in children
Magnesium sulphate versus placebo for acute bronchiolitis in children
Patient or population: children up to 18 months old with acute bronchiolitis
Settings: short stay unit, paediatric emergency department
Intervention: magnesium sulphate
Comparison: placebo
Illustrative comparative risks* (95% CI)












Time to recovery - - - - - Outcome not mea-
sured
Mortality See comment See comment Not estimable 160
(1 RCT)
See comment Trial authors con-
firmed there were
no deaths in either
group (personal
communication)
Adverse events See comment See comment Not estimable 160
(1 RCT)
See comment Neither group re-
ported adverse ef-




Duration of hospital stay Geometric mean
time to discharge
was 25.3 hours in the
placebo group.
Geometric mean time to dis-




See comment Results were tak-
en directly from the
published report.
Clinical severity score (CSS)
(Wang score; range 0 to 12; higher
= poorer outcome)
The mean (SD) CSS
at 24 hours in the
placebo group was
4.55 points (1.62)
The mean CSS at 24 hours
in the magnesium sulphate
group was 0.13 points high-


























































































































































measured at 0 to 24 hours
after treatment
Clinical severity score (CSS)
(Wang score; range 0 to 12; higher
= poorer outcome)
measured at 25 to 48 hours
after treatment
The mean (SD) CSS
at 48 hours in the
placebo group was
4.84 points (1.57)
The mean CSS at 48 hours
in the magnesium sulphate
group was 0.42 points lower









Hospital re-admission within 30
days of discharge
(re-admissions were reported at
14 days)







*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; MD: mean difference; SD: standard deviation; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High quality. Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality. Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality. Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality. We are very uncertain about the estimate.
aWe downgraded the quality of the evidence to very low for indirectness and very serious imprecision (1 study, small sample size, wide confidence intervals).
bWe downgraded the quality of the evidence to low for indirectness and serious imprecision (1 study, small sample size).
 
 
Summary of findings 2.   Magnesium sulphate compared with hypertonic saline for acute bronchiolitis in children
Magnesium sulphate versus hypertonic saline for acute bronchiolitis in children
Patient or population: children up to 12 months old with acute bronchiolitis
Settings: single-centre, emergency department, paediatric intensive care unit and wards
Intervention: magnesium sulphate
Comparison: hypertonic saline
Illustrative comparative risks* (95% CI)Outcomes




























































































































































Hypertonic saline Magnesium sulphate
Time to recovery - - - - - Outcome not
measured
Mortality - - - - - Outcome not
measured
Adverse events - - - - - Outcome not
measured
Duration of hospital stay The mean (SD) dura-
tion of hospital stay in
the hypertonic saline
group was 3.2 days
(1.0)
The mean duration of hos-
pital stay in the magne-
sium sulphate group was









Clinical severity score (CSS)
(RDAI score; range 0 to 17; higher =
poorer outcomes)
measured at 0 to 24 hours
after treatment
- - - - - Outcome not
measured
Clinical severity score (CSS)
(RDAI score; range 0 to 17; higher =
poorer outcomes)
measured at 25 to 48 hours
after treatment
The mean (SD) CSS at
48 hours in the hyper-
tonic saline group was
3.7 points (1.8)
The mean CSS at 48 hours
in the magnesium sul-
phate group was 0.10









Hospital re-admission within 30
days of discharge
- - - - - Outcome not
measured
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; MD: mean difference; SD: standard deviation; RCT: randomised controlled trial; RADI: respiratory distress assessment instrument
GRADE Working Group grades of evidence
High quality. Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality. Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality. Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.



















































































































































aWe downgraded the quality of the evidence to very low for indirectness and very serious imprecision (1 study, small sample size).
 
 
Summary of findings 3.   Magnesium sulphate or magnesium sulphate + salbutamol compared with salbutamol for acute bronchiolitis in children
Magnesium sulphate or magnesium sulphate + salbutamol versus salbutamol for acute bronchiolitis in children
Patient or population: children from 1 month to 24 months old with acute bronchiolitis
Settings: single-centre, short-stay unit, paediatric emergency department
Intervention: magnesium sulphate or magnesium sulphate + salbutamol
Comparison: salbutamol
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes












Time to recovery - - - - - Outcome not measured
Mortality See comment See comment Not estimable 56
(1 RCT)a
- No deaths occurred in any
of the groups (personal
communication)
Adverse events See comment See comment Not estimable 56
(1 RCT)a
- There were no instances of
adverse effects, such as hy-
potension, arrhythmias, or
loss of deep tendon reflex-
es reported in any of the
groups.







The mean duration of hos-
pital stay in the magne-
sium sulphate group was 24
hours (95% CI 25.8 to 47.4).
The mean duration of hos-
pital stay for the magne-
sium sulphate + salbutamol




- Results were taken directly



















































































































































Clinical severity score (CSS)
(Wang score; range 0 to 12; high-
er = poorer outcome)
measured at 0 to 24 hours
after treatment
- - - - - Outcome not measured
Clinical severity score (CSS)
(Wang score; range 0 to 12; high-
er = poorer outcome)
measured 25 to 48 hours
after treatment
- - - - - Outcome not measured
Hospital re-admission within
30 days of discharge
- - - - - Outcome not measured
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; MD: mean difference; SD: standard deviation; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High quality. Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality. Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality. Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality. We are very uncertain about the estimate.
a3-arm trial: magnesium sulphate group (19 children), magnesium sulphate plus salbutamol (19 children), salbutamol (18 children)
 
 
Summary of findings 4.   Magnesium sulphate + epinephrine compared with no treatment or normal saline + epinephrine
Magnesium sulphate + epinephrine versus no treatment or normal saline + epinephrine
Patient or population: children up to 12 months old with acute bronchiolitis
Settings: 3 paediatric departments of 3 hospitals
Intervention: magnesium sulphate + epinephrine
Comparison: no treatment or normal saline + epinephrine

























































































































































Assumed risk Corresponding risk
no treatment or normal
saline + epinephrine
Magnesium sulphate + epineph-
rine
(studies) (GRADE)
Time to recovery - - - - - Outcome not
measured
Mortality - - - - - Outcome not
measured
Adverse events - - - - - Outcome not
measured
Duration of hospital stay The mean (SD) duration
of hospital stay in the
epinephrine group was
84.7 hours (10.1)
The mean (SD) duration of hospital
stay for the magnesium sulphate +
epinephrine group was 0.40 hours










(RDAI score; range 0 to 17;
higher = poorer outcomes)
measured at 0 to 24 hours
after treatment
The mean (SD) CSS at 24
hours in the epinephrine
group was 6.6 points
(2.2)
The mean CSS at 24 hours in the
magnesium sulphate + epinephrine
group was 0.20 points lower (1.06










(RDAI score; range 0 to 17;
higher = poorer outcomes)
measured 25 to 48 hours
after treatment
The mean (SD) CSS at 48
hours in the epinephrine
group was 3.7 points
(2.7)
The mean CSS at 48 hours in the
magnesium sulphate + epinephrine
group was 0.90 points lower (1.75











in 30 days of discharge
- - - - - Outcome not
measured
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; MD: mean difference; SD: standard deviation; RCT: randomised controlled trial
GRADE Working Group grades of evidence



















































































































































Moderate quality. Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality. Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality. We are very uncertain about the estimate.
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B A C K G R O U N D
Description of the condition
Acute bronchiolitis is a lower respiratory tract disease, which
mostly aDects children up to two years of age. Many viral
infections can result in bronchiolitis; respiratory syncytial virus
is the most common aetiological agent, and aDects more than
60% of children with bronchiolitis (Calvo 2010; Hasegawa 2014b;
Mansbach 2012b). Infection induces inflammation of the lower
airways causing bronchiolar wall oedema, resulting in narrowing
of the distal airways. Further tapering of the lumen of these
airways occurs due to increased secretions and cellular debris.
Bronchiolitis may cause significant airway obstruction via the
bronchioles, leading to the need for mechanical ventilation in
some circumstances. Irrespective of the causative virus, clinical
presentation is typical; pathological investigation is not required
for diagnosis. The diagnosis and management of bronchiolitis
vary in diDerent regions of the world. The American Academy of
Pediatrics, together with the European Respiratory Society defined
bronchiolitis as the first episode of wheezing preceded by "a
constellation of clinical symptoms and signs suggestive of a viral
upper respiratory prodrome, followed by increased respiratory
eDort in children less than two years of age" (AAP Subcommittee
2006). In the UK, a Delphi consensus exercise defined bronchiolitis
as "a seasonal viral illness characterised by fever, nasal discharge,
and dry, wheezy cough. On examination, there are fine inspiratory
crackles, a high-pitched expiratory wheeze, or both" (Lakhanpaul
2002). In the UK, the presence of a wheeze is not mandatory
for diagnosis. Most European countries restrict the diagnosis of
bronchiolitis to children up to the age of 12 months. We applied the
AAP Subcommittee 2006 definition for this review. Some risk factors
associated with bronchiolitis severity are low socioeconomic
status, male gender, prematurity, prenatal exposure to steroids,
and maternal smoking (Lanari 2015; Murray 2014).
Acute bronchiolitis imposes a significant burden on healthcare
facilities. Increased rates of bronchiolitis-related emergency
department visits (Carroll 2008; Hasegawa 2014a), and
hospitalisations have been reported (Green 2016; Rivera-Sepulveda
2017). Reports of bronchiolitis range from 26.5% of infants younger
than 12 months to 16.4% of children younger than two years
(Carroll 2008; Muñoz-Quiles 2016). It has been estimated that 17%
of children with bronchiolitis who are admitted to hospital are
treated in intensive care units (Mansbach 2012a). Between 42% and
75% of these children are treated using both invasive and non-
invasive mechanical ventilation techniques (Flores-González 2017;
Mansbach 2012a). Previously, the percentage of children reported
to die from bronchiolitis was 4.2% (Shay 2001). Recent studies show
a mortality rate of 0.24% in hospitalised children (Muñoz-Quiles
2016). However, the number of children with advanced disease has
increased and consequently, healthcare costs have also increased
(Hasegawa 2013).
Description of the intervention
No specific treatment is currently available for acute bronchiolitis.
Treatment involves supportive care, including adequate hydration
and humidified oxygen supplementation. Various treatment
options have been proposed, but only nebulised epinephrine and
hypertonic saline have been shown to be useful (Hartling 2011;
Zhang 2017).
Magnesium is the active component of its sulphate salt of
magnesium, sulphur, and oxygen, and has many diDerent
pharmacological actions. Magnesium is an important cofactor of
many enzymes involved in biological reactions, and is present
in tissues, including the brain, smooth muscles of the uterus,
bronchioles, and the gastrointestinal tract (Swaminathan 2003).
It has many therapeutic uses, such as controlling convulsions,
preventing preterm labour, treating constipation, controlling
tachyarrhythmias, and reversing bronchoconstriction in status
asthmaticus (Schwalfenberg 2017). The action of magnesium on
the bronchioles results in dilation of the airways by several
mechanisms. Use of magnesium sulphate for children with
bronchiolitis is based on its treatment eDectiveness for adults (Kew
2014), and children with asthma (GriDiths 2016).
Treatment with magnesium sulphate may reduce hospital
admissions of children with acute asthma presenting to the
emergency department; evidence on the eDicacy of magnesium
sulphate is required for children with bronchiolitis. Magnesium
sulphate can be administered intravenously or nebulised. The
dose of intravenous magnesium sulphate for a bronchodilation
eDect used in trials ranges from 25 mg/kg/dose to 100 mg/
kg/dose (maximum 2 g; (Alansari 2017; Ciarallo 1996; Scarfone
2000)). Nebulisation doses range from 40 mg/kg (Modaresi 2015),
to 150 mg per dose (Kose 2014). Common adverse eDects of
magnesium sulphate therapy include hypotension (Ciarallo 1996;
Goodacre 2013; Scarfone 2000), cardiac arrhythmias (Goodacre
2013; Lu 2000), and respiratory depression (Lu 2000; Mahajan
2004). Respiratory depression can be monitored by examining deep
tendon reflex; loss of this reflex is the first sign of impending toxicity
(Lu 2000).
How the intervention might work
Acute bronchiolitis results in the narrowing of small distal airways,
causing airflow obstruction. Treatment to dilate airways may prove
useful for children with acute bronchiolitis. Several ways that
magnesium sulphate may act on the bronchiolar wall, resulting
in bronchodilation, have been proposed. Magnesium sulphate has
been shown to dilate bronchial muscle in animal studies (Hirota
1999; Kumasaka 1996; Spivey 1990), and may result in bronchial
smooth muscle relaxation by blocking the voltage-dependent
calcium channels, preventing calcium influx (Gourgoulianis 2004).
Magnesium sulphate decreases acetylcholine accumulation at
nerve endings, further preventing bronchoconstriction (Castillo
1954). Magnesium sulphate may oDer a safe, widely available, and
low-cost therapy to relieve airway obstruction in children with
bronchiolitis.
Why it is important to do this review
Several Cochrane Reviews have investigated treatment options
for children with acute bronchiolitis, including nebulised
deoxyribonuclease (Enriquez 2012), heliox inhalation (Liet 2015),
bronchodilators other than magnesium sulphate (Gadomski 2014),
nebulised epinephrine (Hartling 2011), nebulised hypertonic saline
(Zhang 2017), and steroids (Fernandes 2013). However, none of
these interventions have been adopted as treatment. The role
of magnesium sulphate therapy for bronchiolitis has not been
reviewed previously. This review complements other Cochrane
Reviews, to achieve consensus on treatment for children with acute
bronchiolitis.
Magnesium sulphate for treating acute bronchiolitis in children up to two years of age (Review)
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O B J E C T I V E S
To assess the eDects of magnesium sulphate in acute bronchiolitis
in children up to two years of age.
M E T H O D S
Criteria for considering studies for this review
Types of studies
In the protocol we planned to include randomised controlled trials
(RCTs) and non-RCTs, as we were expecting to identify few RCTs. We
included RCTs only, as we did not identify any non-RCTs.
Types of participants
We included children up to two years of age, diagnosed with acute
bronchiolitis on clinical assessment, irrespective of confirmation of
viral aetiology, presenting to emergency departments, outpatient
departments, admitted to hospital or intensive care units. We did
not exclude studies enrolling children with comorbidities, high
risk factors, or both. Comorbidities and high risk factors for the
population of interest for this review included children younger
than 12 weeks, preterm birth at 34 weeks' gestation or less,
histories of diagnosed chronic lung or congenital heart disease, or
immunodeficiency.
Types of interventions
We compared magnesium sulphate (any dose, route of
administration, or timing) alone, or as an adjunct to conventional
treatments including:
1. nebulised hypertonic saline;
2. nebulised epinephrine; or
3. nebulised bronchodilators.
The possible comparisons were:
1. magnesium sulphate compared with placebo;
2. magnesium sulphate compared with hypertonic saline;
3. magnesium sulphate compared with epinephrine;
4. magnesium sulphate compared with conventional
bronchodilator;
5. magnesium sulphate + bronchodilator compared with no
treatment or normal saline + the same bronchodilator;
6. magnesium sulphate + hypertonic saline compared with no
treatment or normal saline + hypertonic saline;
7. magnesium sulphate + epinephrine compared with no
treatment or normal saline + epinephrine
Types of outcome measures
We added the primary outcome time to recovery, as it is a person-
centred, clinically important outcome, likely to be modified by the
treatment. In the protocol, the primary outcome, clinical severity
score, had four components: clinical severity score measured using
any validated scoring system, duration of mechanical ventilation,
duration of hospital stay, or duration of intensive care unit stay.
We moved clinical severity score to the secondary outcomes, and
separated the four components into four secondary outcomes as
these are diDerent independent outcomes with diDerent meaning.
We specified time points of assessment of the clinical severity
score.
Primary outcomes
1. Time to recovery
2. Mortality
3. Adverse eDects of magnesium sulphate treatment
Secondary outcomes
1. Duration of hospital stay
2. Clinical severity score (at 0 to 24 hours and 25 to 48 hours a@er
treatment) measured using any validated scoring system
3. Pulmonary function test
4. Hospital readmission rate within 30 days of discharge
5. Duration of mechanical ventilation
6. Duration of intensive care unit stay
Search methods for identification of studies
Electronic searches
We searched the following databases: Cochrane Central Register
of Controlled Trials (CENTRAL 2020, Issue 3), in the Cochrane
Library, which includes the Cochrane Acute Respiratory Group's
Specialised Register (searched 30 April 2020); MEDLINE via PubMed
(1966 to 30 April 2020); Embase (1980 to 30 April 2020); LILACS (Latin
American and Caribbean Health Science Information database;
1982 to 30 April 2020), and CINAHL (1992 to 30 April 2020; Appendix
1). We did not apply any language or publication restrictions. We
also searched ClinicalTrials.gov and the World Health Organization
International Clinical Trials Registry Platform (ICTRP; searched 30
April 2020).
Searching other resources
We checked reference lists of all primary studies and review articles
for additional references. We contacted experts in the field to
identify additional, unpublished material.
Data collection and analysis
Selection of studies
Two  review authors (SC, DK) independently screened titles and
abstracts of studies identified as a result of the search, for potential
inclusion in the review. We retrieved full-text study reports of
studies deemed potentially eligible, and two review authors (SC,
DK) independently screened the full text to identify studies for
inclusion, and record reasons for exclusion of ineligible studies. We
resolved any disagreements through discussion, or by consulting a
third review author (NC), if necessary. We identified and excluded
duplicates, and collated multiple reports of the same study so that
each study, rather than each report, was the unit of interest in the
review. We recorded the selection process in a PRISMA flow diagram
(Figure 1), and 'Characteristics of excluded studies' table (Moher
2009).
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Figure 1.   Study flow diagram
 
Data extraction and management
We used a data collection form for study characteristics and
outcome data, which was piloted on at least one study in the
review. One review author (SC) extracted the following study
characteristics from the included studies.
1. Methods: study design, total duration of study, details of any run-
in period, number of study centres and location, study setting,
withdrawals, and date of study
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, inclusion
criteria and exclusion criteria
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported
5. Notes: funding for trial, and notable conflicts of interest for trial
authors.
Two review authors (SC, DK) independently extracted outcome
data from the included studies. We noted if outcome data were
not reported in a usable way in the 'Characteristics of included
studies' tables. We resolved any disagreements by consensus. One
review author (SC) entered data into the Review Manager 5 file
(Review Manager 2014). We double-checked that data were entered
correctly by having a second review author (DK) spot-check study
characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (SC, DK) independently assessed risk of bias for
each study, using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We resolved any
disagreements by discussion, if necessary. We assessed the risk of
bias according to the following domains.
1. Allocation (selection bias)
2. Blinding (performance bias and detection bias)
3. Incomplete outcome data (attrition bias)
4. Selective outcome reporting (reporting bias)
5. Other bias
We graded each potential source of bias as high, low, or unclear, and
provided a quote from the study report, together with a justification
for our judgement in the 'Risk of bias' table. We summarised the
'Risk of bias' judgements across diDerent studies for each of the
domains listed. We considered blinding separately for diDerent
key outcomes where necessary. When information on risk of bias
related to unpublished data, or correspondence with a trialist, we
noted this in the 'Risk of bias' table.
When considering treatment eDects, we took into account the risk
of bias for the studies that contributed to that outcome.
Measures of treatment e<ect
We entered outcome data for each study into the Data and analyses
tables in Review Manager 5 to calculate the treatment eDects
(Review Manager 2014). We used risk ratio (RR) for dichotomous
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outcome, such as hospital readmission rate. We did not analyse
adverse eDects and mortality, as no events were reported.
For continuous outcomes, we calculated mean diDerence (MD),
as we only identified one study for analysis. We planned to use
standardised mean diDerence (SMD) if diDerent scales were used,
but we did not find such data. We confirmed that higher scores
for continuous outcomes had the same meaning for the particular
outcome, explained the direction, and reported if the directions
were reversed, when required. We reported all pooled eDect sizes
with 95% confidence intervals (CIs).
We did not conduct meta-analyses, as the treatments were not
similar enough to pool.
Unit of analysis issues
The unit of analysis was the child. For studies with more than two
arms, we included the relevant arms for analysis, and excluded
other arms. We planned to combine intervention groups to make a
single pair comparison, but we did not find such data.
Dealing with missing data
We contacted investigators to verify key study characteristics, and
to obtain missing numerical outcome data, when needed (e.g.
when a study was identified as abstract only or a diDerent format of
reporting was used by the authors). We did not conduct sensitivity
analyses, as either missing data were not likely to introduce bias, or
data were insuDicient.
Assessment of heterogeneity
We did not measure heterogeneity, as only one study was available
for each comparison.
Assessment of reporting biases
We did not create a funnel plot to explore possible small-study and
publication biases, as we did not include more than 10 trials for any
comparison.
Data synthesis
We planned to pool data from studies that we judged to be clinically
homogeneous, using Review Manager 5 (Review Manager 2014). If
more than one eligible study provided usable data in any single
comparison, we planned to perform a meta-analysis. We did not
find suDicient data for pooling or meta-analysing.
We planned to use the random-eDects model to analyse data, as we
expected the included studies would diDer in terms of intervention
dose, route of delivery, and study location. We used the fixed-eDect
model to calculate eDect size and 95% CIs, as we identified and
included only one study for each comparison.
Subgroup analysis and investigation of heterogeneity
We were unable to conduct analyses for many outcomes, due to
the lack of data. Those outcomes and comparisons are described in
Table 1. We did not perform any of the planned subgroup analyses
due to insuDicient data. Only one study was available for each
comparison.
Sensitivity analysis
We did not conduct any sensitivity analyses due to insuDicient data.
Summary of findings and assessment of the certainty of the
evidence
We created 'Summary of findings' tables using the following
outcomes: time to recovery, mortality, adverse events, duration
of hospital stay, clinical severity score at 0 to 24 hours and at
25 to 48 hours a@er treatment, and hospital readmission rate
within 30 days of discharge. We created a single 'Summary of
findings' table for the comparisons, Magnesium sulphate compared
with conventional bronchodilator, and Magnesium sulphate +
bronchodilator compared with no treatment or normal saline +
same bronchodilator. The intervention groups in both of these
comparisons come from a single trial (Kose 2014). We used
the five GRADE considerations (study limitations, consistency
of eDect, imprecision, indirectness, and publication bias) to
assess the certainty of the body of evidence, as it related to
the studies that contributed data to the meta-analyses for the
prespecified outcomes (Atkins 2004). We used methods and
recommendations described in Section 8.5 and Chapter 12 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011), and GRADEpro GDT so@ware (GRADEpro GDT). We justified
all decisions to downgrade the quality of the evidence in footnotes,
and provided comments to aid readers' understanding of the
review, when necessary.
R E S U L T S
Description of studies
See Characteristics of included studies  and Characteristics of
excluded studies tables for details.
Results of the search
We searched five databases, and retrieved 1200 records to 30 April
2020 (Electronic searches). Searches of other resources, internet,
and expert contacts identified 13 additional records that appeared
to meet the inclusion criteria, bringing our total yield to 1213
records. A@er removal of duplicates, we assessed 904 records,
based on information presented in the title and abstract, and
removed 891 records. We obtained the full text for 13 records. We
excluded three studies, and identified two ongoing studies. We
included four studies, reported in eight publications (Figure 1). We
screened the reference lists of the included publications, but did
not identify any additional randomised controlled trials (RCTs).
We sought additional information from study authors when data
were not reported in a usable way, or were not reported. Two study
authors responded and provided additional data (Alansari 2017;
Kose 2014), one did not respond (Modaresi 2015), and another
could not be contacted (Priya 2018). The authors of two excluded
studies could not provide additional data (Gupta 2015; Rady 2018).
Included studies
Study design
We did not identify any non-RCTs comparing magnesium
sulphate alone, or in addition to conventional treatments, with
any interventions. We included four RCTs, reported in eight
publications. Three studies were published as full-text papers in
peer reviewed journals (Alansari 2017; Kose 2014; Modaresi 2015);
one was a Master's thesis, posted on a university website (Priya
2018). Three RCTs were parallel-arm designs; one included three
parallel arms (Kose 2014).
Magnesium sulphate for treating acute bronchiolitis in children up to two years of age (Review)









Cochrane Database of Systematic Reviews
Setting
The included studies were conducted in Qatar (Alansari 2017),
Turkey (Kose 2014), Iran (Modaresi 2015), and India (Priya 2018).
Three were single-centre studies, and one was a three-centre study
(Modaresi 2015). Three studies enrolled children from emergency
rooms; one study did not specify the setting (Modaresi 2015).
Population
Two studies included children up to 12 months old (Modaresi
2015; Priya 2018), one study included children up to 18 months
(Alansari 2017), and one study included children from 1 month to
24 months old (Kose 2014). Three studies excluded children with a
history of premature birth (Alansari 2017; Kose 2014; Priya 2018);
two studies excluded children with atopy (allergy) history or family
history of asthma (Kose 2014; Modaresi 2015). Two studies used the
Wang score (range 0 to 12; higher scores indicate increased illness
severity) for clinical severity scoring, and included children whose
scores were ≥ 4 (moderate to severe bronchiolitis; (Alansari 2017;
Kose 2014; Wang 1992)). Two studies used the Respiratory Distress
Assessment Instrument (RDAI; range 0 to 17; higher scores mean
increased illness severity; (Lowell 1987)). One included children
whose scores were at least 5 (moderate to severe bronchiolitis;
(Modaresi 2015)). Severity of illness was unclear in Priya 2018.
Intervention
Comparator interventions diDered amongst all four trials: Alansari
2017 compared magnesium sulphate with placebo; Kose 2014
compared it with a bronchodilator (salbutamol); Modaresi 2015
compared magnesium sulphate in combination with epinephrine
with epinephrine alone ; and Priya 2018 compared magnesium
sulphate with hypertonic saline. Three studies administered the
nebulised form of magnesium sulphate to children, and one
administered intravenous magnesium sulphate (Alansari 2017).
Magnesium sulphate was given as a single intravenous dose in
Alansari 2017, as two nebulised doses in Kose 2014, and as multiple
doses until discharge of the child in two studies (Modaresi 2015;
Priya 2018).
Study funding sources
Alansari 2017 was hospital-sponsored, and Modaresi 2015 was
funded by the Child Growth and Development Research Center,
Isfahan University of Medical Sciences. Two studies did not mention
sources of funding (Kose 2014; Priya 2018).
Excluded studies
We excluded three studies (Gupta 2015; Pruikkonen 2018; Rady
2018).
All three studies included diDerent populations; study authors were
unable to provide specific outcome data for children up to two
years old, with the first episode of wheezing.
Gupta 2015 was available as a conference abstract. The trial
enrolled children, of unspecified ages, with first or second
episodes of moderate to severe acute bronchiolitis. We contacted
the trial authors to request data on children with their first
wheezing episode, but additional data were not available. Two
studies examined a diDerent population. Pruikkonen 2018 included
children aged six months to four years, with more than one episode
of wheezing. Rady 2018 included children with wheezy chest of all
causes, between the ages of 2 months and 12 years; the trial authors
were unable to provide details of outcome on children up to two
years old.
Studies awaiting classification
We did not identify any studies awaiting classification.
Ongoing studies
We identified two ongoing trials being conducted in India. Both are
placebo controlled, two parallel-arm trials. CTRI/2017/02/007919
plans to enrol 104 children from 2 to 12 months old.
CTRI/2018/06/014400 plans to enrol 50 children from 1 to
24 months old. The intervention drug in both studies is
the nebulised form of magnesium sulphate, but doses and
frequency of administration diDer. CTRI/2017/02/007919 prescribes
three doses of magnesium sulphate at one hour intervals;
CTRI/2018/06/014400) prescribes magnesium sulphate every 4
hours over 24 hours (6 doses). The primary outcome, bronchiolitis
severity, is measured with the RDAI score in CTRI/2017/02/007919,
and the Wang bronchiolitis severity score in CTRI/2018/06/014400.
See Characteristics of ongoing studies.
Risk of bias in included studies
Figure 2 provides a summary of risk of bias judgements. Figure 3
depicts the risk of bias for each domain, presented as percentages
across all included studies. We assessed two studies at low risk of
bias overall, and two as unclear risk of bias overall.
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Alansari 2017 + ? + + +
Kose 2014 ? ? + + ?
Modaresi 2015 + + + + +
Priya 2018 ? ? + + ?
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Figure 3.   'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item, presented as percentages
across all included studies
Allocation concealment (selection bias)
Blinding (performance bias and detection bias): All outcomes
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
 
Allocation
We judged two studies at low risk of bias for selection bias;
both provided adequate reporting of sequence generation and
allocation (Alansari 2017; Modaresi 2015). Two studies did not
provide adequate information on the method of sequence
generation, and allocation and we rated them as unclear risk of bias
(Kose 2014; Priya 2018).
Blinding
We judged one study, which maintained blinding of investigators
and parents, at low risk of bias (Modaresi 2015). We judged three
studies as unclear risk of bias, because they did not give details
on how they maintained blinding (Alansari 2017; Kose 2014; Priya
2018).
Incomplete outcome data
We considered all four studies to be at low risk of attrition bias;
fewer than two to three children in each intervention group were
lost to follow-up or withdrew from three studies (Alansari 2017;
Kose 2014; Modaresi 2015); no participant data were missing from
Priya 2018.
Selective reporting
We considered all included studies to be at a low risk of bias
for selective reporting. Alansari 2017 reported all outcomes as
specified in the protocol. The protocols for the other three studies
were not available, but they reported all outcomes planned in the
methods section of the published report. We did not detect any
selective omission of outcomes.
Other potential sources of bias
We judged two studies at low risk of other bias (Alansari 2017;
Modaresi 2015). Authors of these trials did not disclose the receipt
of any grants, funds, or shares. We considered two trials as unclear
risk of bias (Kose 2014; Priya 2018). These trials did not mention
sources of funding, or conflicts of interest. There was no imbalance
in baseline clinical severity scores, or other baseline characteristics
of the children in the included studies. We found nothing to suggest
inappropriate administration of study drugs, pre-randomisation
administration of interventions, interim analysis aDecting conduct
of research, or selective reporting of subgroups.
E<ects of interventions
See: Summary of findings 1 Magnesium sulphate compared with
placebo for acute bronchiolitis in children; Summary of findings
2 Magnesium sulphate compared with hypertonic saline for acute
bronchiolitis in children; Summary of findings 3 Magnesium
sulphate or magnesium sulphate + salbutamol compared with
salbutamol for acute bronchiolitis in children; Summary of
findings 4 Magnesium sulphate + epinephrine compared with no
treatment or normal saline + epinephrine
Comparison 1: magnesium sulphate compared with placebo
One RCT, which enrolled 162 children, compared intravenous (IV)
magnesium sulphate with placebo (Summary of findings 1; Alansari
2017). They excluded the data for two enrolled children in the
analysis, because one child was immunodeficient, and the other
was discharged against medical advice. A total of 160 children
were analysed for all outcomes except hospital re-admission rate
(a secondary outcome), for which data from 158 children were
analysed.
Primary outcomes
1. Time to recovery
This outcome was not measured.
2. Mortality
We contacted the trial authors, who confirmed there were no
deaths in either group (Alansari 2019).
3. Adverse e<ects of magnesium sulphate treatment
There were no reported incidences of adverse eDects, such as
apnoea, cyanosis, or haemodynamic instability in either group.
Secondary outcomes
1. Duration of hospital stay
Alansari 2017 did not measure simple (arithmetic) mean and
standard deviation (SD), but instead, measured geometric means.
Geometric mean is equal to the exponential of the mean of the
log-transformed values. The value of geometric mean is lesser than
the arithmetic mean. Geometric mean is not much aDected by
the skewed distribution of data. We contacted the trial authors to
request simple mean and SD. Although we received a response, the
trial authors did not provide the requested data (Alansari 2019). We
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did not calculate arithmetic means from the geometric mean for
this analysis, because there was only one study available for this
comparison. Geometric mean time until discharge was 24.1 hours
in the magnesium sulphate group and 25.3 hours in the placebo
group.
2. Clinical severity score (at 0 to 24 hours and 25 to 48 hours aJer
treatment) measured using any validated scoring system
Alansari 2017 reported clinical severity scores for bronchiolitis at
a number of time points up to 72 hours post-treatment, using the
Wang score. The magnesium sulphate group included 78 children,
and the placebo group included 82 children at all measurement
time points. Mean bronchiolitis severity scores at baseline were
6.85 points (SD 1.30) in the magnesium sulphate group, and 6.97
points (SD 1.17) in the placebo group. The study found no statistical
diDerences in clinical severity score at any time point.
Clinical severity score at 0 to 24 hours aJer treatment
The mean clinical severity score at 24 hours was 4.68 points
(SD 0.94) in the magnesium sulphate group, and 4.55 points (SD
1.62) in the placebo group. It is uncertain whether magnesium
sulphate improves clinical severity score at 24 hours (MD 0.13, 95%
confidence interval (CI) -0.28 to 0.54; 1 RCT; 160 children; very low-
certainty evidence; Analysis 1.1).
Clinical severity score at 25 to 48 hours aJer treatment
The mean clinical severity score at 48 hours was 4.42 points (SD
1.08) in the magnesium sulphate group, and 4.84 points (SD 1.57)
in the placebo group. It is uncertain whether magnesium sulphate
reduces clinical severity score at 48 hours (MD -0.42, 95% CI -0.84
to -0.00; 1 RCT; 160 children; very low-certainty evidence; Analysis
1.2).
3. Pulmonary function test
This outcome was not measured.
4. Hospital readmission rate within 30 days of discharge
Hospital readmission rates within 14 days of discharge were
available. Fi@een children in the magnesium sulphate group
and five children in the placebo group were readmitted to
an infirmary or hospital. Magnesium sulphate may increase
hospital readmissions amongst children up to two years old with
bronchiolitis, compared with placebo (risk ratio (RR) 3.16, 95% CI
1.20 to 8.27; 1 RCT; 158 children; low-certainty evidence; Analysis
1.3).
5. Duration of mechanical ventilation
None of the children were mechanically ventilated.
6. Duration of intensive care unit stay
The mean duration of intensive care unit stay was 101.00 hours in
the magnesium sulphate group (SD not available; there was only
one child in the magnesium sulphate group), and 154.37 hours
(SD 62.62) in the placebo group. Although the mean duration was
shorter in the magnesium sulphate group, it is uncertain whether
magnesium sulphate reduced duration of intensive care unit stay
compared with placebo, due to the small number of participants (1
RCT; 160 children; very low-certainty evidence).
Comparison 2: magnesium sulphate compared with
hypertonic saline
One RCT, which enrolled 220 children, compared nebulised
magnesium sulphate with hypertonic saline (Summary of findings
2; Priya 2018).
Primary outcomes
1. Time to recovery
This outcome was not measured.
2. Mortality
This outcome was not measured. The thesis did not describe
mortality. We were unsuccessful in our attempts to contact the
study author or thesis supervisor.
3. Adverse e<ects of magnesium sulphate treatment
This outcome was not measured.
Secondary outcomes
1. Duration of hospital stay
The mean duration of hospital stay was 3.2 days (SD 1.1) in the
magnesium sulphate group, and 3.2 days (SD 1.0) in the hypertonic
saline group. It is uncertain whether there is a diDerence between
magnesium sulphate and hypertonic saline on duration of hospital
stay (MD 0.00, 95% CI -0.28 to 0.28; 1 RCT; 220 children; very low-
certainty evidence; Analysis 2.1).
2. Clinical severity score (at 0 to 24 hours and 25 to 48 hours aJer
treatment) measured using any validated scoring system
The study used the RDAI score for clinical severity for bronchiolitis,
measured at a number of time points until discharge. The
magnesium sulphate and hypertonic saline groups each included
110 children at all time points. Mean bronchiolitis severity scores at
baseline were 8.0 points (SD 1.8) in the magnesium sulphate group,
and 7.9 points (SD 1.7) in the hypertonic saline group.
Clinical severity score at 0 to 24 hours aJer treatment
This outcome was not measured.
Clinical severity score at 25 to 48 hours aJer treatment
The mean clinical severity score at 48 hours was 3.8 points (SD
1.9) in the magnesium sulphate group, and 3.7 points (SD 1.8) in
the hypertonic saline group. It is uncertain whether magnesium
sulphate improves clinical severity score at 48 hours (MD 0.10, 95%
CI -0.39 to 0.59; 1 RCT; 220 children; very low-certainty evidence;
Analysis 2.2).
3. Pulmonary function test
This outcome was not measured.
4. Hospital readmission rate within 30 days of discharge
This outcome was not measured.
5. Duration of mechanical ventilation
This outcome was not measured. The study only included children
with mild to moderate bronchiolitis; they excluded children with
severe bronchiolitis.
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6. Duration of intensive care unit stay
This outcome was not measured.
Comparison 3: magnesium sulphate compared with
epinephrine
None of our included trials compared magnesium sulphate with
epinephrine.
Comparison 4: magnesium sulphate compared with
conventional bronchodilator
We included one RCT, enrolling 57 children, which compared
nebulised magnesium sulphate with salbutamol, a conventional
bronchodilator (Summary of findings 3; Kose 2014). One child
in the magnesium sulphate group was withdrawn due to
deteriorating clinical status. Children were allocated to one of
three interventional arms: magnesium sulphate (19 children);
salbutamol (18 children); and salbutamol + magnesium sulphate
(19 children). We used data from two study arms (the magnesium
sulphate group and the salbutamol group, N = 37 children) for
analysis.
Primary outcomes
1. Time to recovery
This outcome was not measured.
2. Mortality
The trial authors confirmed that no deaths occurred in either group
(Kose 2019).
3. Adverse e<ects of magnesium sulphate treatment
There were no reported incidences of adverse eDects, such as
hypotension, arrhythmias, or loss of deep tendon reflexes in either
group (Kose 2019).
Secondary outcomes
1. Duration of hospital stay
The trial authors did not provide the SD for duration of hospital stay,
but reported the 95% CI (Kose 2019). We did not calculate the SD
from the 95% CI for this analysis because: 1) there was only a single
study available for this comparison; 2) there were very few children
in either intervention arm; and 3) the 95% CIs were not symmetrical.
The mean duration of hospital stay was 24 hours (95% CI 25.8 to
47.4) in the magnesium sulphate group, and 24 hours (95% CI 23.4
to 76.9) in the salbutamol group. It is uncertain whether magnesium
sulphate has any eDect on duration of hospital stay compared with
salbutamol, a conventional bronchodilator (1 RCT; 37 children; very
low-certainty evidence).
2. Clinical severity score (at 0 to 24 hours and 25 to 48 hours aJer
treatment) measured using any validated scoring system
The study used the Wang score for clinical severity for bronchiolitis,
and documented scores at one and four hours a@er treatment, but
not at 24 or 48 hours a@er treatment.
Clinical severity score at 0 to 24 hours aJer treatment
This outcome was not measured.
Clinical severity score at 25 to 48 hours aJer treatment
This outcome was not measured.
3. Pulmonary function test
This outcome was not measured (Kose 2019).
4. Hospital readmission rate within 30 days of discharge
This outcome was not measured (Kose 2019).
5. Duration of mechanical ventilation
No children were mechanically ventilated (Kose 2019).
6. Duration of intensive care unit stay
No children required admission for intensive care (Kose 2019).
Comparison 5: magnesium sulphate + bronchodilator
compared with no treatment or normal saline + the same
bronchodilator
We included one RCT, enrolling 57 children, which
compared nebulised magnesium sulphate with a conventional
bronchodilator (salbutamol; Summary of findings 3; Kose 2014).
Children were allocated to one of three interventional arms:
magnesium sulphate (19 children); salbutamol (18 children); and
salbutamol + magnesium sulphate (19 children). We used data from
two study arms (magnesium sulphate + salbutamol group and the
no treatment or normal saline + salbutamol group; N = 37 children)
for the analyses.
Primary outcomes
1. Time to recovery
This outcome was not measured.
2. Mortality
The trial authors confirmed there were no deaths in either group
(Kose 2019).
3. Adverse e<ects of magnesium sulphate treatment
There were no reported incidences of adverse eDects, such as
hypotension, arrhythmias, or loss of deep tendon reflexes in either
group (Kose 2019).
Secondary outcomes
1. Duration of hospital stay
The trial authors did not provide the SD for duration of hospital
stay, but reported the 95% CI. We did not calculate the SD from the
95% CI for this analysis because: 1) there was only a single study
available for this comparison; 2) there were very few children in
either intervention arm; and 3) the 95% CIs were not symmetrical.
The mean duration of hospital stay was 20 hours (95% CI 15.3 to
39.0) in the magnesium sulphate + salbutamol group, and 24 hours
(95% CI 23.4 to 76.9) in the salbutamol group. Due to very low-
certainty evidence, the eDect of magnesium sulphate + salbutamol
on duration of hospital stay is uncertain.
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2. Clinical severity score (at 0 to 24 hours and 25 to 48 hours aJer
treatment) measured using any validated scoring system
The study used the Wang score for clinical severity for bronchiolitis,
and documented it at one and four hours a@er treatment, but not
at 24 or 48 hours a@er treatment.
Clinical severity score at 0 to 24 hours aJer treatment
This outcome was not measured.
Clinical severity score at 25 to 48 hours aJer treatment
This outcome was not measured.
3. Pulmonary function test
This outcome was not measured (Kose 2019).
4. Hospital readmission rate within 30 days of discharge
This outcome was not measured (Kose 2019).
5. Duration of mechanical ventilation
No children were mechanically ventilated (Kose 2019).
6. Duration of intensive care unit stay
No children required intensive care admission (Kose 2019).
Comparison 6: magnesium sulphate + hypertonic saline
compared with no treatment or normal saline + hypertonic
saline
No trials compared magnesium sulphate + hypertonic saline versus
no treatment or normal saline + hypertonic saline.
Comparison 7: magnesium sulphate + epinephrine compared
with no treatment or normal saline + epinephrine
We included one RCT, with 125 enrolled children, which compared
these interventions (Summary of findings 4; Modaresi 2015). Data
from 120 children (60 in each group) were available for analysis;
three children from the magnesium sulphate group and two
children from the epinephrine group were lost during follow-up.
The trial authors did not respond to our request for additional data.
Primary outcomes
1.Time to recovery
This outcome was not measured.
2. Mortality
This outcome was not measured.
3. Adverse e<ects of magnesium sulphate treatment
This outcome was not measured.
Secondary outcomes
1. Duration of hospital stay
The mean duration of hospital stay was 84.3 hours (SD 9.7) in the
magnesium sulphate + epinephrine group, and 84.7 hours (SD 10.1)
in the epinephrine group (MD -0.40, 95% CI -3.94 to 3.14; 1 RCT; 120
children; very low-certainty evidence; Analysis 3.1).
2. Clinical severity score (at 0 to 24 hours and 25 to 48 hours aJer
treatment) measured using any validated scoring system
The study used the RDAI score for clinical severity for bronchiolitis,
and documented it at a number of time points until discharge.
The mean bronchiolitis severity scores at baseline were 11.4 points
(SD 2.7) in the magnesium sulphate + epinephrine group, and 11.0
points (SD 2.7) in the epinephrine group.
Clinical severity score at 0 to 24 hours aJer treatment
The mean clinical severity score at 24 hours was 6.4 points (SD 2.6)
in the magnesium sulphate + epinephrine group, and 6.6 points (SD
2.2) in the epinephrine group. It is uncertain whether magnesium
sulphate + epinephrine reduces clinical severity score at 24 hours
compared with epinephrine alone (MD -0.20, 95% CI -1.06 to 0.66; 1
RCT; 120 children; very low-certainty evidence; Analysis 3.2).
Clinical severity score at 25 to 48 hours aJer treatment
The mean clinical severity score at 48 hours was 2.8 points (SD 2.0)
in the magnesium sulphate + epinephrine group, and 3.7 points (SD
2.7) in the epinephrine group. It is uncertain whether magnesium
sulphate + epinephrine reduces clinical severity score at 48 hours
compared with epinephrine alone (MD -0.90, 95% CI -1.75 to -0.05;
1 RCT; 120 children; very low-certainty evidence; Analysis 3.3).
3. Pulmonary function test
This outcome was not measured.
4. Hospital readmission rate within 30 days of discharge
This outcome was not measured.
5. Duration of mechanical ventilation
This outcome was not measured.
6. Duration of intensive care unit stay
This outcome was not measured.
D I S C U S S I O N
Summary of main results
We included four randomised controlled trials (RCT; 564 children).
Each trial compared magnesium sulphate, either alone or in
combination, with diDerent interventions. Of seven proposed
comparisons, data were available for five. Studies compared
magnesium sulphate with placebo or no treatment, a conventional
bronchodilator, or hypertonic saline. No treatment was standard
care, epinephrine, or salbutamol for both groups. If measured, the
outcomes were reported by a single trial only, resulting in low-
quality or very low-quality evidence for all outcomes.
Therefore, we are uncertain about the eDects of magnesium
sulphate on mortality, adverse events, the duration of hospital stay,
clinical severity at 24 or 48 hours, or the risk of readmission within
30 days.
None of the studies reported on two of our primary outcomes,
time to recovery and mortality. However, correspondence with
authors of two trials confirmed there were no deaths in any of the
groups (Alansari 2017; Kose 2014). It may be that mortality rates
associated with acute bronchiolitis are low, and only one study
included children with severe bronchiolitis, while three studies
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included children with moderate disease severity. The studies
either reported no adverse events, or did not measure them as an
outcome.
Duration of hospital stay was reported in diDerent formats in each
study, but there was little or no diDerence found between groups.
EDects on clinical severity at 24 or 48 hours were uncertain for
magnesium sulphate alone compared to placebo or hypertonic
saline, or when combined with epinephrine and compared to
normal saline + epinephrine.
Pulmonary function tests were not measured in any of the included
trials. Hospital re-admission rate within 30 days of discharge
was measured by one trial. Magnesium sulphate may increase
hospital readmission rate within 14 days of discharge compared
with placebo. Duration of mechanical ventilation and intensive care
unit stay were not available for any comparison.
We found that the available evidence was insuDicient to establish
the eDicacy and safety of magnesium sulphate due to single studies
analysing small numbers of children for each comparison.
Overall completeness and applicability of evidence
The available evidence is insuDicient to determine the superiority
or inferiority of magnesium sulphate over other treatments for
children with acute bronchiolitis. Our searches identified relevant
studies, abstracts, and ongoing studies. Of the four included
studies, only Alansari 2017 had a published protocol available,
and reported all predefined outcomes. The overall applicability
of the evidence was low, due to imprecision and risk of bias.
Studies diDered regarding intervention groups, and could not be
pooled for analysis. No studies were available for two comparisons:
magnesium sulphate versus epinephrine, and magnesium sulphate
+ hypertonic saline versus no treatment or normal saline +
hypertonic saline. The evidence determining the role of magnesium
sulphate on the primary outcome, time to recovery, was not
available, as this outcome was not measured in any of the trials.
There was a lack of data for the remaining primary outcomes,
mortality and adverse events. Evidence from single studies only
were available for the remainder of the outcomes.
Quality of the evidence
We used GRADE methods to assess the overall certainty of evidence.
We assessed it as very low for most outcomes for which data
were available, due to very serious imprecision (i.e. single trial
analysing few participants for each comparison). We assessed
the domains regarding allocation and blinding as unclear, which
suggests incomplete reporting. We assessed one trial at low risk of
bias for all domains; and one trial at unclear risk of bias in most
domains.
Potential biases in the review process
The search strategy was designed to detect both RCTs and
non-RCTs, and it is unlikely that relevant studies were not
identified and assessed. We attempted to obtain additional
information from the trial authors as required. Two review authors
independently screened the search results, determined studies
for inclusion, assessed risk of bias, extracted relevant data, and
conducted GRADE assessments. We resolved discrepancies with an
independent review author three times, regarding risk of bias and
GRADE assessment. There were some deviations from the protocol,
but these were unlikely to introduce bias. We could not assess
publication bias due to the small number of studies available. It
is possible that some studies with negative results were missed, if
they were not available in the public domain.
Agreements and disagreements with other studies or
reviews
We did not find any published reviews that addressed the same
clinical question considered in our review.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
There are insuDicient data and evidence to establish the eDicacy
and safety of magnesium sulphate for children under two years of
age with acute bronchiolitis. We are uncertain, if compared with
placebo, magnesium sulphate may be associated with an increased
readmission rate within 14 days of discharge from hospital (low-
certainty evidence).
There is no evidence available for our primary outcome, time
to recovery, for any comparison; and no evidence for secondary
outcomes, duration of mechanical ventilation, intensive care unit
stay, and pulmonary function.
Implications for research
Well-designed randomised controlled trials to assess the eDects
of magnesium sulphate for children with acute bronchiolitis are
needed. Future trials enrolling children from diDerent settings,
and including very ill children with bronchiolitis are also needed.
Outcomes, such as time to recovery, adverse eDects, need for
mechanical ventilation, duration of mechanical ventilation, need
for intensive care unit admission, and duration of intensive care
unit stay must be included.
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Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Trial registration: NCT02145520
Study design: randomised, double-blind placebo-controlled study
Setting and centres: single-centre, short stay unit, Paediatric Emergency Center, Hamad General Hos-
pital, Qatar
Dates of study: October 2012 to May 2015
Duration of study: until child discharged
Inclusion criteria: children aged ≤ 18 months, with moderate to severe viral bronchiolitis, with prodro-
mal history consistent with viral upper respiratory tract infection, followed by wheezing or crackles on
auscultation, or both, and a Wang bronchiolitis severity score ≥ 4 on presentation
Exclusion criteria: children were excluded if they had 1 or more of the following characteristics:
preterm birth ≤ 34 weeks' gestation, previous history of wheezing, steroid use within 48 hours of pre-
sentation, obtundation and progressive respiratory failure requiring intensive care unit admission, his-
tory of apnoea within 24 hours before presentation, oxygen saturation ≤ 85% on room air, history of a
diagnosis of chronic lung disease, congenital heart disease, immunodeficiency, exposure to varicella
within 21 days before enrolment, known magnesium or calcium metabolism disturbance, or known ad-
verse reaction to magnesium sulphate
Participants Randomised: 162 infants; 80 in the magnesium group and 82 in the placebo group.
Analysed: 160 infants; 78 in the magnesium group and 82 in the placebo group; 2 enrolled infants
could not be included in the analysis: 1 was immunodeficient and 1 was discharged against medical ad-
vice
Analysis for follow-up: at 2 weeks: 158 infants; magnesium 77; placebo 81 (2 children were lost to fol-
low-up, 1 from each group)
Age: (mean (SD)) was 4 (3) months in the magnesium group and 5 (4) months in the placebo group
Gender distribution: (male: female) was 58:22 in the magnesium group and 48:34 in the placebo group
Baseline Wang bronchiolitis severity score: mean (SD) was 6.85 (1.30) in the magnesium group and
6.97 (1.17) in the placebo group
Interventions Intervention: 100 mg/kg magnesium sulphate intravenously by a syringe pump over 60 minutes; sin-
gle dose
Comparator: placebo; 0.9% saline
Concomitant treatment in both study arms: 5 mL nebulised 5% hypertonic saline in 1 mL 1:1000 epi-
nephrine given at 4 hour intervals throughout the infirmary stay
Alansari 2017 
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Outcomes Planned outcomes: the study protocol was available, so we could determine the planned outcomes.
Primary outcome was improvement percentage of discharge after a dose of intravenous magnesium
sulphate (time frame: time to medical readiness for discharge).
Secondary outcomes were
1. Improvement of bronchiolitis clinical severity score using Wang score at 4, 8, 12, 24, 36, 48, 60, and
72 hours
2. Need for admission to intensive care unit during the initial visit
3. Other outcomes within 2 weeks after discharge were:
• need for clinical revisit;
• need for infirmary or observation unit admission; and
• need for intensive care unit admission.
Reported outcomes: all outcomes planned in study protocol were reported in the paper.
Outcome data not provided in a usable way for improvement percentage of discharge after a dose of
intravenous magnesium sulphate. Study authors used geometric mean (95% CI) time until discharge
and expressed results as ratio of geometric mean time in 2 interventions. Mean (SD) was not provided
by the authors.
Notes Funding source: this study was hospital sponsored by Hamad Medical Corporation
Conflicts of interest: none
Comment: the study did not provide mean and standard deviations for clinical severity score at vari-
ous time points. They included a bar chart from which it was difficult to obtain the exact scores. The tri-
al author provided this information in the form of a table.
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Low risk Adequate methods of sequence generation and allocation concealment used.
"Randomisation was stratified into two groups, patients with a history of
eczema and/or known to have a parent or full sibling with prior physician diag-
nosis of asthma, and patients without. Block randomisation was used for allo-
cation".
Blinding (performance
bias and detection bias)
All outcomes




Low risk Only 1 child was lost to follow-up in either group, and excluded from analysis
Selective reporting (re-
porting bias)
Low risk Outcomes planned in the protocol were reported in the published report
Other bias Low risk None of the trial authors disclosed receipt of any grants, funds, or shares from
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Study characteristics
Methods Trial registration: not traceable
Study design: double-blind, prospective clinical trial
Setting and centres: single-centre, short-stay unit, Pediatric Emergency Department of Erciyes Univer-
sity Hospital, Central Anatolia, Kayseri, Turkey
Dates of study: October 2012 to March 2013
Duration of study: until child was discharged
Inclusion criteria: children aged 1 to 24 months, history of preceding viral upper respiratory infection
followed by wheezing and crackles on auscultation, first wheezing episode, and clinical severity score 4
to 8 on admission. Viral respiratory infection was diagnosed on clinical grounds.
Exclusion criteria: infants with clinical severity score < 4 or > 8, oxygen saturation (SaO2) < 86 % in
room air, chronic cardiopulmonary or neurological disease, premature birth, birthweight < 2500 g, his-
tory of recurrent wheezing episodes, history of atopy, proven immune deficiency, age < 1 month or > 2
years, proven or suspected acute bacterial infection, previous treatment with bronchodilators or corti-
costeroids, the presence of symptoms > 7 days, proven asthma in parents and siblings, and consolida-
tion or atelectasis on a chest roentgenogram
Participants Randomised: 57 infants
Analysed: 56 infants; magnesium 19; salbutamol 18; salbutamol plus magnesium sulphate 19 (1 child
in the magnesium sulphate group subsequently withdrew because of deteriorated clinical status
Analysis for follow-up: there was no follow-up of participants
Age: median age (min to max) was 7.5 (3 to 19) months in the salbutamol group; 8 (4 to 22) months in
the magnesium sulphate group; and 8 (3 to 21) months in the salbutamol + magnesium sulphate group
Gender distribution (male:female) was 12:6 in the salbutamol group; 12:7 in the magnesium sulphate
group; and 13:6 in the magnesium sulphate + salbutamol group
Baseline clinical severity score: mean (95% CI) clinical severity score was 5.9 (5.4 to 6.4) in the salbu-
tamol group; 6.1 (5.6 to 6.5) in the magnesium sulphate group; and 6.3 (5.7 to 6.8) in the salbutamol +
magnesium sulphate group
Baseline heart rate: mean heart rate was 149.4 (95% CI 136.9 to 161.8) in the salbutamol group; 147.8
(95% CI 139.4 to 156.1) in the magnesium sulphate group; and 156.7 (95% CI 149.2 to 165.2) in the
salbutamol + magnesium sulphate group
Interventions Intervention: inhaled magnesium sulphate 150 mg, diluted to 4 mL with 0.9 % saline solution
Comparator:
1. Salbutamol: salbutamol group received inhalation of salbutamol (Ventolin, GlaxoSmithKline, Middle-
sex, UK), 0.15 mg/kg, diluted to 4 mL with 0.9% saline solution
2. Salbutamol + magnesium sulphate: received inhalation of salbutamol 0.15 mg/kg + inhaled magne-
sium sulphate 150 mg, diluted to 4 mL with 0.9% saline solution
All groups received medications twice, at 30-minute intervals
Outcomes Planned outcomes: no protocol available
Reported outcomes: main outcomes were:
1. clinical severity score, (at 0, 60, 240 minutes of the study);
2. heart rate, (at 0, 60, 240 minutes of the study);
3. duration of hospitalisation (hours); and
Kose 2014 
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4. complication rates. Hypotension, arrhythmias, and loss of deep tendon reflexes were studied before
and after each dose was administered.
Outcome data not provided in a usable way for duration of hospital stay. Authors used mean (95% CI)
time and expressed result as P value for significance comparing two interventions. Mean (SD) was not
provided by the trial authors
Notes Funding source: not mentioned
Conflicts of interest: none
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Unclear risk "All eligible patients were randomly assigned to one of the three groups".
Details of randomisation method, or how randomisation was done were not
available
Blinding (performance
bias and detection bias)
All outcomes
Unclear risk The trial report mentioned double-blinded study, but did not report for whom,




Low risk 1 child in the magnesium sulphate group subsequently withdrew because of
deteriorating clinical status. This was unlikely to affect results
Selective reporting (re-
porting bias)
Low risk The planned outcomes in the methods section were reported in the results
section





Methods Trial registration: not traceable
Study design: double-blind randomised clinical trial
Setting and centres: 3 hospitals paediatric departments, Isfahan University of Medical Sciences, Isfa-
han, Iran
Dates of study: January 2010 to December 2011
Duration of study: until child was discharged
Inclusion criteria: acute onset of respiratory distress, positive wheezing on physical examination,
chest radiograph compatible with bronchiolitis, aged < 12 months, and RDAI score of at least 5
Exclusion criteria: family history of asthma; chronic pulmonary, cardiac, neurologic and oncologic dis-
ease; previous use of glucocorticoids, bronchodilators or monoamine oxidase inhibitors (MAOI); tachy-
cardia exceeding 200 beats per minute; tachypnoea exceeding 100 breaths per minute
Participants Randomised: 125 infants. 2 study arms: magnesium sulphate + epinephrine 63; epinephrine 62
Analysed: magnesium sulphate + epinephrine 60; epinephrine 62. Three children in the magnesium
sulphate + epinephrine group, and two children in the epinephrine group were subsequently with-
drawn because of deteriorating clinical status
Modaresi 2015 
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Analysis for follow-up: there was no follow-up of participants
Age: mean (SD) age was 5.2 (2.1) months in the magnesium sulphate + epinephrine group; 4.8 (3.2)
months in the epinephrine group
Gender distribution: (male:female) was 34:26 in the magnesium sulphate + epinephrine group; 38:22
in the epinephrine group
Baseline clinical severity score: mean (SD) 11.4 (2.7) in the magnesium sulphate plus epinephrine
group; 11 (2.7) in the epinephrine group
Baseline heart rate: mean (SD) 104 (5) in the magnesium sulphate + epinephrine group; 104 (4) in the
epinephrine group
Baseline O2 saturation: mean (SD) 88 (1) in the magnesium sulphate + epinephrine group; 87 (1) in the
epinephrine group
Interventions Intervention: 40 mg/kg magnesium sulphate (3.25%) and 0.1 mL/kg epinephrine (1/1000) mixed with
normal saline nebulisation
Comparator: 0.1 mL/kg epinephrine (1/1000) mixed with normal saline nebulisation
Concomitant treatment in both groups: 0.1 mL/kg epinephrine (1/1000) mixed with normal saline
nebulisation
All groups received 3 doses of each medication at 20-minute intervals, and then every 4 hours
Outcomes Planned outcomes: no protocol available
Reported outcomes: primary outcome was length of hospital stay (defined as the time from the first





4. respiratory rate; and
5. use of ventilatory support.
All outcomes recorded at admission, first 20 minutes, second 20 minutes, third 20 minutes, after 4
hours, and then daily during hospitalisation
Notes Funding source: supported financially by Child Growth and Development Research Center, Isfahan
University of Medical Sciences, Isfahan, Iran
Conflicts of interest: none
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Low risk Adequate methods of sequence generation and allocation concealment used.
Random number tables and third party randomisation were used
Blinding (performance
bias and detection bias)
All outcomes





Low risk 3 children in the magnesium sulphate + epinephrine group and 2 children in
the epinephrine group were subsequently withdrawn because of deteriorating
clinical status
Modaresi 2015  (Continued)
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Selective reporting (re-
porting bias)
Low risk The planned outcomes in the methods section were reported in the results
section
Other bias Low risk None of the trial authors disclosed receipt of any grants, or funds, or shares





Methods Trial registration: not traceable
Study design: single-blind randomised controlled trial
Setting and centres: single-centre, emergency department, paediatric intensive care unit and wards
of Institute of Social Paediatrics, Stanley Medical College and Hospital, Tamilnadu, India.
Dates of study: January 2017 to September 2017
Duration of study: until child was discharged
Inclusion criteria: children less than 12 months old, with acute onset of respiratory symptoms associ-
ated with fever, cough, tachypnoea, or chest radiograph findings consistent with bronchiolitis (such as
hyperinflation), and first episode of wheezing
Exclusion criteria: previous history of wheezing
1. History of chronic pulmonary, cardiac, neurologic, and immunological disorders
2. Previous use of steroids and bronchodilators
3. History of prematurity (< 34 weeks' gestation)
4. Radiographic evidence of pneumonia
5. Severe bronchiolitis
Participants Randomised: 220 infants. 2 study arms: nebulised magnesium sulphate 110; nebulised hypertonic
saline 110
Analysed: magnesium sulphate 110; hypertonic saline 110. No missing data.
Analysis for follow-up: none
Age: the mean (SD) age was 7.1 (3.1) months in the magnesium sulphate group; 6.9 (3) months in the
hypertonic saline group.
Gender distribution: (male:female) 63:47 in the magnesium sulphate group; 63:47 in the hypertonic
saline group.
Baseline clinical severity score (RDAI): mean (SD) 8.0 (1.8) in the magnesium sulphate group; 7.9 (1.7)
in the hypertonic saline group
Interventions Intervention: magnesium sulphate; 0.1 to 0.2 mL/kg/dose of 25% magnesium sulphate, mixed to 4 mL
with 0.9% normal saline nebulisation
Comparator: 4 mL hypertonic saline nebulisation
All children received medications at 20-minute intervals for the first 3 doses, and then every 4 hours
Concomitant treatment in both groups: none mentioned
Outcomes Planned outcomes: no protocol available
Priya 2018 
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Reported outcomes:
1. length of hospital stay; and
2. RDAI score, recorded at 0, 20, 40 minutes, 1 hour, then every 12 hours until discharge
Notes Funding source: not mentioned
Conflicts of interest: not mentioned
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Unclear risk Deatails of randomisation not available. Sealed envelopes used, but it is not
known whether these were sequentially numbered and opaque
Blinding (performance
bias and detection bias)
All outcomes
Unclear risk Authors reported the study to be single-blinded, but due to unclear alloca-




Low risk There were no dropouts
Selective reporting (re-
porting bias)
Low risk The planned outcomes in the methods section were reported in the results
section









Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Gupta 2015 The study was published as a conference abstract. It included children presenting with first or sec-
ond episodes of moderate to severe acute bronchiolitis. Trial authors responded, but could not
provide additional data related to first episodes of bronchiolitis (inclusion criteria for this review).
Pruikkonen 2018 Study population did not match the review inclusion criteria. Trial authors included children with
more than one episode of wheezing, while inclusion eligibility was limited to children with first
episode of wheezing in this review, as per the definition by AAP Subcommittee 2006.
Rady 2018 This study included children with a wheezy chest from all causes, which is not part of our inclusion
criteria. The trial authors stated that they included infants and children between 2 months and 12
years. However, the trial authors could not provide details of outcomes on children up to 2 years of
age, which was part of our inclusion criteria for this review.
 
Characteristics of ongoing studies [ordered by study ID]
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Study name CTRI/2017/02/007919
Methods Trial registration: CTRI/2017/02/007919
Study design: randomised, parallel-group, placebo-controlled trial
Setting and centres: single centre, emergency department, Department of Paediatrics, GMSH,
Chandigarh, India
Dates of study: first enrolment 12 January 2017
Duration of study: intervention duration: 3 hour; outcome assessment duration: until child was
discharged
Inclusion criteria: children aged 2 to 12 months with diagnosis of acute bronchiolitis, with short
history of cough, with or without fever of less than 7 days duration, wheezing on examination, first
attack of wheezing.
Exclusion criteria: past history of wheezing, family history of bronchial asthma, presence of con-
genital heart disease or congenital malformation, history of prematurity or mechanical ventilation
in newborn period, pneumonia or pleural effusion, SAM, very sick child with shock, seizures, tachy-
cardia (HR > 200/minute), and respiratory failure, foreign body ingestion, history of nebulisation of
any drug
Participants Plan to randomise 104 infants
Interventions Intervention: magnesium sulphate nebulisation: enrolled cases in the intervention group shall be
given 40 mg/kg magnesium sulphate nebulisation, diluted with 2 mL to 3 mL normal saline. 3 doses
of medication will be given at 1-hour intervals, and will not be repeated after 3 doses
Comparator: oxygen therapy, IV fluids or oral feeds: this group will be treated with oxygen therapy,
IV fluids, or oral feeds, symptomatic treatment for fever, and supportive care
Concomitant treatment in both study arms: none written
Outcomes Primary outcomes: improvement in severity of bronchiolitis, measured with the Respiratory Dis-
tress Assessment Instrument (RDAI) score. Timepoint: RDAI score shall be assessed at admission, at
3, 6, 12, 18, 24, 36, 48, 60, 72, 84, 96 hours, and at discharge.
Secondary outcomes:
1. Duration of hospital stay; time point: at discharge
2. Improvement in SpO2; time point: improvement in SpO2 assessed at admission, at 3, 6, 12, 18, 24,
36, 48, 60, 72, 84, 96 hours, and at discharge
Starting date 12 January 2017
Contact information Name: Dr Neeraj Dhawan
Email: ndhawan_6144@yahoo.com; p.sadbhavna@yahoo.com







Magnesium sulphate for treating acute bronchiolitis in children up to two years of age (Review)









Cochrane Database of Systematic Reviews
Methods Trial registration: CTRI/2018/06/014400
Study design: randomised, parallel-group, placebo-controlled trial
Setting and centres: single centre in India
Dates of study: first enrolment 2 July 2018
Duration of study: interventions: 24 hours; follow-up: 2 weeks
Inclusion criteria: infants aged 1 month to 24 months presenting to paediatric emergency or OPD,
with diagnosis of bronchiolitis and BSS ≥ 4, and guardian of child willing to give informed consent
Exclusion criteria:
1. Previous history of wheezing
2. Those requiring mechanical ventilation
3. Children with haemodynamically significant heart disease, chromosomal anomalies, immunod-
eficiency, cystic fibrosis, bronchopulmonary dysplasia, or epileptic encephalopathy
Participants Randomised: plan to randomise 50 Infants
Analysed: not available
Analysis for follow-up at 2 weeks: not available
Age: infants 1 month to 24 months of age
Gender distribution: not available
Baseline Wang bronchiolitis severity score: > 4
Interventions Intervention: nebulisation with 3 mL 3.2% magnesium sulphate every 4 hours for 24 hours, in ad-
dition to standard care. Oxygen saturation will be noted before starting treatment, and oxygen will
be supplemented if < 92%. If the saturation falls below 90% in either group, and persists despite
oxygen supplementation, the child will be considered for ventilation.
Comparator: standard care: maintenance of adequate hydration and oxygenation
Concomitant treatment in both study arms: none written
Outcomes Primary outcomes: to compare improvement of bronchiolitis severity scores between treatment
groups.
Secondary outcomes:
1. Need for admission to intensive care unit during the initial visit in both groups
2. Within 2 weeks after discharge:
• Need for clinic revisit
• Need for hospital admission
• Need for ICU admission
Starting date 12 January 2017
Contact information Name: Dr Daisy Khera
Email daisykhera78@gmail.com
Department of Pediatrics AIIMS Jodhpur, Jodhpur, Rajasthan, India
Notes  
CTRI/2018/06/014400  (Continued)
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OPD: out patient department
BSS: bronchiolitis severity score




D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Magnesium sulphate compared with placebo for acute bronchiolitis in children
Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
1.1 Clinical severity score at 0 to 24 hours
after treatment




1.2 Clinical severity score at 25 to 48
hours after treatment




1.3 Hospital readmission rate within 30
days of discharge






Analysis 1.1.   Comparison 1: Magnesium sulphate compared with placebo for acute


















IV, Fixed, 95% CI
0.13 [-0.28 , 0.54]
Mean Difference
IV, Fixed, 95% CI
-1 -0.5 0 0.5 1
Favours magnesium sulphate Favours placebo
 
 
Analysis 1.2.   Comparison 1: Magnesium sulphate compared with placebo for acute


















IV, Fixed, 95% CI
-0.42 [-0.84 , -0.00]
Mean Difference
IV, Fixed, 95% CI
-1 -0.5 0 0.5 1
Favours magnesium sulphate Favours placebo
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Analysis 1.3.   Comparison 1: Magnesium sulphate compared with placebo for acute














M-H, Fixed, 95% CI
3.16 [1.20 , 8.27]
Risk Ratio
M-H, Fixed, 95% CI
0.02 0.1 1 10 50
Favours magnesium sulphate Favours placebo
 
 
Comparison 2.   Magnesium sulphate compared with hypertonic saline for acute bronchiolitis in children
Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size




2.2 Clinical severity score at 25 to 48
hours after treatment






Analysis 2.1.   Comparison 2: Magnesium sulphate compared with hypertonic


















IV, Fixed, 95% CI
0.00 [-0.28 , 0.28]
Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
Favours magnesium sulphate Favours hypertonic saline
 
 
Analysis 2.2.   Comparison 2: Magnesium sulphate compared with hypertonic saline for acute


















IV, Fixed, 95% CI
0.10 [-0.39 , 0.59]
Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
Favours magnesium sulphate Favours hypertonic saline
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Comparison 3.   Magnesium sulphate + epinephrine compared with no treatment or normal saline + epinephrine for
acute bronchiolitis in children
Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size




3.2 Clinical severity score at 0 to 24
hour after treatment




3.3 Clinical severity score at 25 to 48
hour after treatment






Analysis 3.1.   Comparison 3: Magnesium sulphate + epinephrine compared with no treatment or
normal saline + epinephrine for acute bronchiolitis in children, Outcome 1: Duration of hospital stay
Study or Subgroup
Modaresi 2015















IV, Fixed, 95% CI
-0.40 [-3.94 , 3.14]
Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
Favours magnesium sulphate + epinephrine Favours epinephrine
 
 
Analysis 3.2.   Comparison 3: Magnesium sulphate + epinephrine compared with no treatment or normal saline +
epinephrine for acute bronchiolitis in children, Outcome 2: Clinical severity score at 0 to 24 hour aJer treatment
Study or Subgroup
Modaresi 2015















IV, Fixed, 95% CI
-0.20 [-1.06 , 0.66]
Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
Favours magnesium sulphate + epinephrine Favours epinephrine
 
 
Analysis 3.3.   Comparison 3: Magnesium sulphate + epinephrine compared with no treatment or normal saline +
epinephrine for acute bronchiolitis in children, Outcome 3: Clinical severity score at 25 to 48 hour aJer treatment
Study or Subgroup
Modaresi 2015















IV, Fixed, 95% CI
-0.90 [-1.75 , -0.05]
Mean Difference
IV, Fixed, 95% CI
-4 -2 0 2 4
Favours magnesium sulphate + epinephrine Favours epinephrine
 
 
A D D I T I O N A L   T A B L E S
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Outcome Comparison Reason for not conducting
analysis
Time to recovery All comparisons No data available
Magnesium sulphate compared with placebo
magnesium sulphate compared with conventional bronchodilator
Magnesium sulphate + bronchodilator compared with no treatment or
normal saline + the same bronchodilator
No deaths reported
Magnesium sulphate compared with hypertonic saline
Mortality
Magnesium sulphate + epinephrine compared with no treatment or nor-
mal saline + epinephrine
No data available
Magnesium sulphate compared with placebo
Magnesium sulphate compared with conventional bronchodilator
Magnesium sulphate + bronchodilator compared with no treatment or
normal saline + the same bronchodilator
No adverse effects reported
Magnesium sulphate compared with hypertonic saline
Adverse effects of mag-
nesium sulphate treat-
ment
Magnesium sulphate + epinephrine compared with no treatment or nor-
mal saline + epinephrine
No data available
Magnesium sulphate compared with placebo Reporting format was dif-
ferent. Study authors used
geometric mean timea.
We did not transform data
for analysis, as only single
study was available for this
comparison.
Magnesium sulphate compared with conventional bronchodilator
Duration of hospital
stay
Magnesium sulphate + bronchodilator compared with no treatment or
normal saline + the same bronchodilator
Reporting format was dif-
ferent. Study authors used
95% confidence interval.
We did not transform data
for analysis, as only single
study was available for this
comparison.
Magnesium sulphate compared with hypertonic saline
Magnesium sulphate compared with conventional bronchodilator
Clinical severity score at
0 to 24 hours after treat-
ment
Magnesium sulphate + bronchodilator compared with no treatment or
normal saline + the same bronchodilator
No data available
Magnesium sulphate compared with conventional bronchodilatorClinical severity score
at 25 to 48 hours after
treatment Magnesium sulphate + bronchodilator compared with no treatment or
normal saline + the same bronchodilator
No data available
Table 1.   Comparisons and outcomes for which analyses could not be conducted 
Magnesium sulphate for treating acute bronchiolitis in children up to two years of age (Review)









Cochrane Database of Systematic Reviews
Pulmonary function test All comparisons No data available
Hospital readmission
rate within 30 days of
discharge
All comparisons except magnesium sulphate compared with placebo No data available
Duration of mechanical
ventilation
All comparisons No data available
Duration of intensive
care unit stay
All comparisons No data available
Table 1.   Comparisons and outcomes for which analyses could not be conducted  (Continued)
Note: these analyses were planned in the protocol, but were not carried out due to limited or no available data.
aGeometric mean is equal to the exponential of the mean of the log-transformed values. The value of geometric mean is usually lesser than
the arithmetic mean. Geometric mean is used as it is not much aDected by the skewed distribution of data.
 
 
A P P E N D I C E S









#9 Respiratory Syncytial Viruses[MeSH:NoExp]
#10 Respiratory Syncytial Virus, Human[MeSH]
#11 Respiratory Syncytial Virus Infections[MeSH]
#12 Respiratory Syncytial Virus[tiab]
#13 Respiratory Syncytial Viruses[tiab]
#14 rsv[tiab]
#15 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12








#23 #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22
#24 #15 AND #23
#25 animals [mh] NOT humans [mh]
#26 #24 NOT #25
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#9 'pneumovirus'/de
#10 'human respiratory syncytial virus'/exp
#11 'respiratory syncytial virus infection'/exp
#12 "respiratory syncytial virus":ti,ab
#13 "respiratory syncytial viruses":ti,ab
#14 rsv:ti,ab








#23 #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22
#24 #15 AND #23
#25 'animal '/exp NOT 'human '/exp
#26 #24 NOT #25
Appendix 3. CENTRAL search (via Wiley)
#1 MeSH descriptor: [Bronchiolitis] explode all trees
#2 "bronchiolitis":ti,ab,kw (Word variations have been searched)
#3 "bronchiolitides":ti,ab,kw (Word variations have been searched)
#4 bronchiole*:ti,ab,kw (Word variations have been searched)
#5 bronchial:ti,ab,kw (Word variations have been searched)
#6 "bronchiolar":ti,ab,kw (Word variations have been searched)
#7 bronchodilat*:ti,ab,kw (Word variations have been searched)
#8 bronchoconstrict*:ti,ab,kw (Word variations have been searched)
#9 MeSH descriptor: [Respiratory Syncytial Viruses] this term only
#10 MeSH descriptor: [Respiratory Syncytial Virus, Human] explode all trees
#11 MeSH descriptor: [Respiratory Syncytial Virus Infections] explode all trees
#12 "respiratory syncytial virus":ti,ab,kw (Word variations have been searched)
#13 "respiratory syncytial viruses":ti,ab,kw (Word variations have been searched)
#14 "RSV":ti,ab,kw (Word variations have been searched)
#15 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14
#16 MeSH descriptor: [Magnesium Sulfate] explode all trees
#17 MeSH descriptor: [Magnesium Compounds] this term only
#18 MeSH descriptor: [Magnesium] explode all trees
#19 MgSO4*:ti,ab,kw (Word variations have been searched)
#20 Mg S04*:ti,ab,kw (Word variations have been searched)
#21 "magnesium":ti,ab,kw (Word variations have been searched)
#22 #16 or #17 or #18 or #19 or #20 or #21
#23 #15 and #22
#24 MeSH descriptor: [Animals] explode all trees
#25 MeSH descriptor: [Humans] explode all trees
#26 #24 not #25
#27 #23 not #26
Appendix 4. LILACS Virtual health library search
mh:C08.127.446.135$ OR Bronquiolitis OR Bronquiolite OR bronchiolitis OR bronchiolitides OR bronchiole* OR bronchial OR bronchiolar
OR bronchodilat* OR bronchoconstrict* OR mh:"Respiratory Syncytial Viruses" OR mh:"Respiratory Syncytial Virus, Human" OR
mh:"Respiratory Syncytial Virus Infections" OR (Virus AND Sincitial AND Respiratorio) OR (Vírus AND Respiratório AND Sincicial) OR
respiratory syncytial virus OR respiratory syncytial viruses OR rsv) AND (mh:"Magnesium Sulfate" OR mh:"Magnesium Compounds" OR
mh:"Magnesium" OR Magnesio OR Magnésio OR mgso4* OR "mg s04*" OR magnesium
Appendix 5. CINAHL EBSCO search
S27 S23 NOT S26
S26 S24 NOT S25
S25 (MH "Human")
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S24 (MH "Animals+")
S23 S15 AND S22
S22 S16 OR S17 OR S18 OR S19 OR S20 OR S21
S21 TI Magnesium OR AB Magnesium
S20 TI Mg S04* OR AB Mg S04*
S19 TI MgSO4* OR AB MgSO4*
S18 (MH "Magnesium")
S17 (MH "Magnesium Compounds+")
S16 (MH "Magnesium Sulfate")
S15 S1 OR S2 OR S3 OR S4 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S13 OR S14
S14 TI rsv OR AB rsv
S13 (MH "Respiratory Syncytial Virus Infections")
S12 TI "Respiratory syncytial virus" OR AB "Respiratory syncytial virus"
S11 TI "Respiratory Syncytial Viruses" OR AB "Respiratory Syncytial Viruses"
S10 (MH "Respiratory Syncytial Viruses")
S9 TI pneumovirus OR AB pneumovirus
S8 TI bronchoconstrict* OR AB bronchoconstrict*
S7 TI bronchodilat* OR AB bronchodilat*
S6 TI bronchiolar OR AB bronchiolar
S5 TI bronchial OR AB bronchial
S4 TI bronchiole* OR AB bronchiole*
S3 TI bronchiolitides OR AB bronchiolitides
S2 TI Bronchiolitis OR AB Bronchiolitis
S1 (MH "Bronchiolitis+")
H I S T O R Y
Protocol first published: Issue 2, 2018
Review first published: Issue 12, 2020
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S O U R C E S   O F   S U P P O R T
Internal sources
• PGIMER and Dr RML Hospital, New Delhi and PGIMER, Chandigarh, India
Library and Internet facility
External sources
• No sources of support supplied
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
1. In the protocol, we planned to include non-randomised controlled trials (non-RCTs), as we were expecting to identify few studies. In the
review, we only included RCTs, as we did not identify any non-RCTs.
2. We added the primary outcome, time to recovery, as it is a person-centred, and clinically important outcome, likely to be modified by
the treatment.
3. In the protocol, the primary outcome, clinical severity score, had four components: clinical severity score measured using any validated
scoring system, duration of mechanical ventilation, duration of hospital stay, or duration of intensive care unit stay. These could not be
described under one outcome. Therefore, we separated these into four outcomes. We moved 'clinical severity score' to the secondary
outcomes.
4. We did not specify time points of clinical severity score in the protocol. Clinical severity scoring was conducted at multiple time points
amongst the studies. Therefore, we specified the time points of clinical severity score at 0 to 24 hours, and 25 to 48 hours a@er treatment
for the review.
5. There was a change in authorship: Arun K Yadav, an author on the protocol, did not co-author the review.
6. We planned to meta-analyse using the random-eDects model, as we anticipated the studies would diDer. We used the fixed-eDect model
to calculate eDect size and 95% confidence intervals (CIs) when we could not pool results, and included only one study for comparison.
7. We planned to conduct sensitivity and subgroup analyses. However, there were insuDicient data.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Acute Disease;  Albuterol  [therapeutic use];  Bias;  Bronchiolitis  [*drug therapy];  Bronchodilator Agents  [administration & dosage]
 [*therapeutic use];  Drug Therapy, Combination  [methods];  Epinephrine  [therapeutic use];  Length of Stay;  Magnesium Sulfate
 [administration & dosage]  [*therapeutic use];  Patient Readmission  [statistics & numerical data];  Placebos  [therapeutic use]; 
Randomized Controlled Trials as Topic;  Saline Solution  [therapeutic use];  Severity of Illness Index
MeSH check words
Humans; Infant; Infant, Newborn
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